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Letters to the Editor 
Dear Editor 
Problems encountered using nebulized medications in 
hospitals 
We read with interest the recent paper in Respira- 
tory Medicine by Caldwell and Milroy highlighting 
some of the problems encountered using nebulized 
medications in hospitals (1). While their paper con- 
centrated mainly on the use of nebulized broncho- 
dilators, nebulized antimicrobials are increasingly 
used in the treatment of chronic pulmonary infection 
and for prophylaxis. We recently conducted a survey 
of the use of nebulized antimicrobial agents within 
the West Midlands to estimate how frequently these 
agents are used in clinical practice, how well defined 
their use is, and how well health and safety issues 
arising from their use are addressed. At present not 
all are licensed for this use or produced in a formu- 
lation specifically for use with nebulizers. In addition, 
a number are recognized respiratory sensitizers and 
some may have other adverse health effects (2-5). 
Thus, through inadequate guidance and poor prac- 
tice when using nebulized antimicrobial agents, there 
is potential for less than optimal treatment being 
given to patients, and at the same time some risk of 
adverse effects to staff and others. 
A postal questionnaire was sent to all consult- 
ant physicians, paediatricians, and geriatricians 
employed by West Midlands Regional Health 
Authority at 1 January 1993 seeking information 
about inpatient and outpatient prescription of 
nebulized antimicrobial drugs within the past year 
(1992-1993). 
Consultants provided information on agents used, 
the number of patients treated, number of treatment 
courses, and usual dose prescribed. Details were also 
sought on whether nebulizer type and flow rate were 
specified, and any exhaust filter or local exhaust 
ventilation used. 
Two hundred and ninety-five questionnaires were 
sent and 226 returned (76%). Of those who replied, 20 
of 129 physicians (16%), 15 of 64 paediatricians 
(23%) and one of 33 geriatricians (3%) had used 
nebulized antimicrobial agents in the past year (Table 
1). Colistin, pentamidine, amoxycillin, and gen- 
tamicin had been used for both inpatients and out- 
patients, ribavirin and netilmicin had been used for 
inpatients, and carbenicillin and tobramycin had 
been used for outpatients. The maximum number of 
agents prescribed by any consultant was five. Colistin 
was the agent prescribed by the largest number of 
consultants. Ribavirin and pentamidine were the next 
most commonly prescribed. Prescribed dosages for 
colistin were found to vary widely (250 000 to 
2 000 000 units per nebulization for adults) but 
dosages of other drugs were less variable. 
Most consultants specified a nebulizer type, and 
most either specified a flow rate or used a fixed rate 
Table I Use of nebulized antimicrobial agents by consultants in the West Midlands Region 
Number 
prescribing 
(“Al) 
Nebulizer type Flow 
specified specified 
(%I prescribing) 
Exhaust 
used 
Physicians (129) 
inpatients 
outpatients 
Paediatricians (64) 
inpatients 
outpatients 
Geriatricians (33) 
inpatients 
outpatients 
All consultants (226) 
inpatients 
outpatients 
13 (10) 9 (69) 11 (65) 9 (69) 
17 (13) 14 (82) 16 (94) 12 (71) 
13 (20) 11 (85) 9 (69) 5 (38) 
9 (14) 8 (89) 8 (89) 4 (4) 
l(3) 0 (0) l(100) 0 (0) 
0 (0) 
27 (12) 20 (74) 21 (78) 14 (52) 
26(12) 22 (85) 24 (92) 16 (62) 
0954-61 I l/95/10071 1+05 $12.0010 (Cl 1995 W. B. Saunders Company Ltd 
712 Letters to the Editor 
compressor. A smaller proportion specified the use 
of an exhaust device. Ribavirin and colistin were 
used most frequently without an exhaust device. Only 
one of seven consultants used pentamidine without 
an exhaust device. All these drugs were given on 
occasions without any exhaust device being used. 
Thus, nebulized antimicrobial agents had been 
prescribed by a significant proportion of consultant 
physicians and paediatricians, but by fewer geriatri- 
cians. This use potentially exposes hospital staff, 
patients, visitors, and home carers to health risks 
caused by waste aerosol, and possibly an increased 
risk of infection (3-6). Dosages prescribed for 
colistin, the drug most commonly used in this way, 
varied eight-fold, but the doses of other agents used 
seem to be more standardized. 
Unnecessary exposure of health care staff to waste 
aerosol could be reduced by the wider use of exhaust 
devices, but simple measures such as regular checks 
of equipment connections and seals, and use of 
separate treatment rooms should not be overlooked. 
In addition it would seem sensible that manufac- 
turers and clinicians should recognize that these 
agents are sometimes used in unlicensed ways, 
collaborate to produce formulations for use in 
nebulizers, and specify appropriate treatment regimes 
and safety precautions. 
J. R. BEACH, M. CAMPBELL, 
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Dear Editor 
Cattle TB: ‘VL, open’ cases . . . or ‘NVL, 
non-infectious’ cases? 
There seem to be two schools of thought on the 
issue of cattle TB, and yet it is one of critical 
importance in tackling the final stages of tuberculosis 
eradication schemes. On the one hand it is claimed 
that only cattle with gross ‘visible lesions’ (VL) at 
abattoir inspection are capable of passing TB on to 
other cattle (14). 
This view is not substantiated by other studies 
of cattle aetiology and pathogenesis. Most TB in 
adult cattle starts as a lung infection of respiratory 
aerogenous derivation via aerosolized ‘sputum’ or 
dust. Primary lesions may heal, but more usually 
they remain ‘open’, and may remain subclinically 
latent, or progress to chronic, or fatal and acute 
bronchopneumonia. Even where an apparent 
‘sealed tubercle’ develops, it would seem that intra- 
canalicular bronchiolar spread continues, such that 
intermittent or continuous bacterial shedding occurs 
in the ‘sputum’. Even cattle with micro-lesions that 
would be missed at gross abattoir inspection are 
infectious to other cattle despite being ‘non-visibly- 
lesioned’ (NVL) in the lungs, or VL only in 
broncho-mediastinal lymph nodes. Such cattle 
will be producing infectious faeces via swallowed 
‘sputum’ (559). Surely it is the case that the 
number of cattle with TB in a herd merely 
reflects the period elapsed since the last ‘clear’ test, 
NVL or otherwise, there is spread to contiguous 
herds, and slurry is infectious? Pigs, other stock 
and badgers might catch TB from even NVL 
herds? 
M. HANCOX 
I7 Nouncells Cross 
Stroud 
Gloucester, U.K. 
2 May 1995 
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